Detalhe da pesquisa
1.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer
; 127(8): 1246-1259, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33270904
2.
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
Biol Blood Marrow Transplant
; 24(2): 343-352, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055682
3.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Blood
; 125(19): 3024-31, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814532
4.
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Haematologica
; 102(2): 391-400, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846611
5.
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.
Blood
; 124(25): 3817-27, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25316679
6.
Isolated clonal cytogenetic abnormalities after high-dose therapy.
Biol Blood Marrow Transplant
; 20(8): 1130-8, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24732780
7.
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Transplant Cell Ther
; 29(3): 182.e1-182.e8, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36587740
8.
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Br J Haematol
; 158(2): 198-207, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22594769
9.
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica
; 97(11): 1736-42, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22733022
10.
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Leuk Lymphoma
; 62(13): 3192-3203, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34323164
11.
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Leukemia
; 34(6): 1563-1576, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900407
12.
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Blood Adv
; 4(20): 5078-5088, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080006
13.
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
Clin Cancer Res
; 23(4): 899-907, 2017 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27551000
14.
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Clin Cancer Res
; 23(3): 697-706, 2017 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503200
15.
Tyrosine kinase inhibitor induced isolated pericardial effusion.
Case Rep Oncol
; 8(1): 88-93, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25848358
16.
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
J Clin Oncol
; 33(28): 3152-61, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26261255
17.
Advances in treating acute myeloid leukemia.
F1000Prime Rep
; 6: 96, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25374674
18.
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
Leuk Res
; 38(3): 411-7, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24439051
19.
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
Leuk Res
; 83: 106174, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31255938
20.
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Clin Cancer Res
; 18(24): 6723-31, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23092873